MRRPhysical AI
intelligence
← Company intelligence

Robot maker · registered

Promaxo

Corporate marketmedicalCurated record
promaxo.com

Promaxo integrates portable low-field MRI, AI-driven lesion localization, and robotic needle guidance into a single point-of-care platform for prostate cancer diagnosis and treatment. The MRI platform received FDA 510(k) clearance in March 2021 as the first US office-based portable MRI for prostatic lesion localization and biopsy. The system operates without facility shielding upgrades and is deployed in urology offices and outpatient surgical centres. A dedicated robotic guidance module is in development and pending separate FDA clearance.

HeadquartersOakland, US
Founded2016
Corporate funding$98M
Team51-200
Deployments3
Open roles0
01

Company overview

Identity and operating footprint

Company typeRobot maker
Market segmentCorporate
StageSeries C
FoundersAmit Vohra (CEO & President), Michael Bartholomew (Co-founder), Irving Weinberg (Co-founder)
Regions servedUS
Countries deployedNot listed
Service footprintNot listed
Last reviewed2026-07-05
MX

Robot models

Specifications remain vendor-claimed

Machinemedical

Promaxo MRI System

  • FDA 510(k) cleared for office-based MRI-guided prostate biopsy and treatment

    First US office-use portable single-sided low-field MRI system cleared for prostatic lesion localization and interventional guidance

    Claim source
DP

Deployment log

Announced and cited only

AnnouncedCustomerSiteCountryCountEvidence
2023-02-01Mount Sinai Health SystemhospitalUSNot disclosedAnnouncement
2023-02-01UTHealth HoustonhospitalUSNot disclosedAnnouncement
2021-03-08Mississippi UrologymedicalUSNot disclosedAnnouncement
CA

Funding history

Publicly announced rounds

Investors on recordZepp LabsMicroPort OrthopedicsKineticosBand of AngelsK2XZynext Ventures
TL

Company timeline

Milestones and announcements

2024-06-18Zynext Ventures (VC arm of Zydus Lifesciences) announces strategic investmentPR Newswire
2021-03-08FDA 510(k) clearance granted for office-based MRI-guided prostate biopsy systemBusinessWire
2021-03-03510(k) Premarket Notification K202518 Promaxo MRI System ↗U.S. Food and Drug Administration
SC

Source ledger

12 unique public sources

01
SEC Form D: $26,848,795 sold of $28,781,164 offeringSEC EDGAR · retrieved 2026-07-05
02
Zynext Ventures announces investment in PromaxoPR Newswire · retrieved 2026-07-05
03
SEC Form D: $41,939,728 sold of $57,304,100 offeringSEC EDGAR · retrieved 2026-07-05
04
Promaxo Raises $4.17M in Funding Round Led by Huami CorporationBusiness Wire · retrieved 2026-07-05
05
SEC Form D: $10,971,981 sold of $30,604,200 offeringSEC EDGAR · retrieved 2026-07-05
06
Medical Technology Startup Promaxo Closes $8M Round of FinancingPRWeb · retrieved 2026-07-05
07
Medical Device Developer Promaxo Closes Second Tranche of Series A FundingPRWeb · retrieved 2026-07-05
08
Medical Device Developer Promaxo Closes $3.5 Million Series A Funding RoundPRWeb · retrieved 2026-07-05
09
Promaxo Receives 510(k) Clearance from the FDA for its Innovational MRI PlatformBusinessWire · retrieved 2026-07-05
10
Promaxo Announces Clinical Collaboration with Mount Sinai Health System and UTHealth HoustonPromaxo · retrieved 2026-07-05
11
Promaxo Receives 510(k) Clearance from the FDA for its Innovational MRI PlatformPromaxo · retrieved 2026-07-05
12
Promaxo focal therapy LinkedIn update naming clinical usersPromaxo LinkedIn · retrieved 2026-07-05